Immunocore Holdings plc IMCR
30.48 USD -1.17 (-3.71%)
At closeNov 12, 2026, 4:01 PM EST
30.48 0.00 0.00%
After hours · Nov 12, 4:01 PM ET
30.08 Day range 31.65
27.50 52-week range 40.72
- YTD
- -12.20%
- 1 year
- -13.64%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Immunocore Holdings, Lowers Price Target to $80 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and lowers the price target from $100 to $80.
globenewswire.com Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company…- benzinga.com Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease Control Rate Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
globenewswire.com Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients…
benzinga.com Immunocore Hldgs Q3 EPS $(0.28) Misses $(0.10) Estimate, Sales $102.222M Miss $113.438M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. The company reported quarterly sales of $102.222…
globenewswire.com Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
benzinga.com Immunocore To Present Phase 1/2 Trial Data Evaluating Brenetafusp Alone And In Combination With KIMMTRAK In HLA-A*02:01-Positive Patients With Metastatic Uveal Melanoma, At 2026 SITC Annual Meeting Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingClinical data for…
benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
benzinga.com Immunocore Hldgs Q2 2026 Earnings Call Transcript Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…- benzinga.com Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026 Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve
benzinga.com JP Morgan Reinstates Overweight on Immunocore Holdings, Announces $50 Price Target JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and announces $50 price target.
benzinga.com Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20)…- benzinga.com Mizuho Maintains Neutral on Immunocore Holdings, Raises Price Target to $35 Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and raises the price target from $34 to $35.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Immunocore Hldgs Q1 EPS $0.25 Beats $(0.25) Estimate, Sales $106.677M Miss $107.731M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.25) by 200 percent. This is a 150 percent increase over earnings of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
benzinga.com Reported Sunday, KIMMTRAK Five-Year Phase 3 Data Shows Doubled Survival Likelihood Versus Investigator's Choice With Median OS Of 21.6 Months Versus 16.9 Months In Metastatic Uveal Melanoma KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaOS benefit observed across key subgroups, including patients with high…
benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.- benzinga.com FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
- benzinga.com Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting(OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026)…
benzinga.com Jefferies Downgrades Immunocore Holdings to Hold, Lowers Price Target to $33 Jefferies analyst Clara Dong downgrades Immunocore Holdings (NASDAQ:IMCR) from Buy to Hold and lowers the price target from $48 to $33.- benzinga.com Needham Maintains Buy on Immunocore Holdings, Raises Price Target to $75 Needham analyst Gil Blum maintains Immunocore Holdings (NASDAQ:IMCR) with a Buy and raises the price target from $71 to $75.
benzinga.com Immunocore Holdings Q4 Earnings Report: What Investors Need to Know - benzinga.com Immunocore Hldgs Q4 EPS $(0.60) Misses $(0.23) Estimate, Sales $104.478M Miss $107.310M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.23) by 164.32 percent. This is a 27.66 percent decrease over losses of…
- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Insights into Immunocore Hldgs's Upcoming Earnings - benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Raises Price Target to $36 Morgan Stanley analyst Andrew Galler maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and raises the price target from $34 to $36.
- benzinga.com Immunocore Releases Phase 1 Data For IMC-I109V Showing That It Has A Manageable Safety Profile And Demonstrates Antiviral Activity, Including Reductions In HBsAg Levels, Consistent With Its Mechanism Of Action Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activityIMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by…
- benzinga.com Immunocore Hldgs Q3 Sales $103.693M Beat $100.186M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly sales of $103.693 million which beat the analyst consensus estimate of $100.186 million by 3.50 percent. This is a 29.22 percent increase over sales…
- benzinga.com Wells Fargo Initiates Coverage On Immunocore Holdings with Overweight Rating, Announces Price Target of $60 Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Immunocore Holdings (NASDAQ:IMCR) with a Overweight rating and announces Price Target of $60.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
- benzinga.com Immunocore Hldgs Q2 EPS $(0.20) Beats $(0.23) Estimate, Sales $97.964M Beat $94.428M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.79 percent. This is a 13.04 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research
- benzinga.com Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Holdings (NASDAQ:IMCR) with a Buy and maintains $100 price target.
- benzinga.com Oppenheimer Maintains Outperform on Immunocore Holdings, Raises Price Target to $86 Oppenheimer analyst Jeff Jones maintains Immunocore Holdings (NASDAQ:IMCR) with a Outperform and raises the price target from $85 to $86.
- benzinga.com Immunocore Hldgs Q1 GAAP EPS $0.10 Beats $(0.39) Estimate, Sales $93.88M Beat $88.52M Estimate Immunocore Hldgs (NASDAQ:IMCR) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.39) by 125.64 percent. This is a 120.41 percent increase over losses of…
benzinga.com Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - benzinga.com Earnings Scheduled For February 26, 2025
- benzinga.com Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- benzinga.com Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
- benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
- benzinga.com Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Applied Therapeutics, Inc.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Earnings Scheduled For March 1, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.